Loading...
CanSino Biologics Inc.
6185.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$44.34
HK$-0.46(-1.03%)
CanSino Biologics Inc. (6185.HK) Financial Performance & Income Statement Overview
Review CanSino Biologics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
138.97%
↑ 138.97%
Operating Income Growth
80.18%
↑ 80.18%
Net Income Growth
74.45%
↑ 74.45%
Operating Cash Flow Growth
81.58%
↑ 81.58%
Operating Margin
-47.92%
↓ 47.92%
Gross Margin
65.58%
↑ 65.58%
Net Profit Margin
-45.74%
↓ 45.74%
ROE
-7.47%
↓ 7.47%
ROIC
0.00%
CanSino Biologics Inc. (6185.HK) Income Statement & Financial Overview
Review CanSino Biologics Inc.'s (6185.HK) income statement with detailed quarterly and annual figures.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $261.05M | $186.85M | $112.31M | $169.55M |
| Cost of Revenue | $54.84M | $75.56M | $46.23M | $1.05B |
| Gross Profit | $206.22M | $111.29M | $66.08M | -$878.93M |
| Gross Profit Ratio | $0.79 | $0.60 | $0.59 | -$5.18 |
| R&D Expenses | $86.37M | $68.73M | $96.75M | $176.31M |
| SG&A Expenses | $117.23M | $109.23M | $90.90M | $266.12M |
| Operating Expenses | $199.61M | $184.24M | $195.45M | $353.48M |
| Total Costs & Expenses | $254.45M | $259.80M | $241.69M | $1.40B |
| Interest Income | $12.53M | $15.36M | $23.43M | $24.86M |
| Interest Expense | $14.69M | $18.05M | $14.67M | $18.19M |
| Depreciation & Amortization | $11.63M | $56.40M | $60.10M | $60.10M |
| EBITDA | $18.23M | $23.20M | -$90.68M | -$1.36B |
| EBITDA Ratio | $0.07 | $0.12 | -$0.81 | -$8.04 |
| Operating Income | $6.60M | -$72.95M | -$129.37M | -$957.15M |
| Operating Income Ratio | $0.03 | -$0.39 | -$1.15 | -$5.65 |
| Other Income/Expenses (Net) | -$3.06M | $18.63M | -$32.38M | $434.35M |
| Income Before Tax | $3.54M | -$51.24M | -$161.75M | -$522.80M |
| Income Before Tax Ratio | $0.01 | -$0.27 | -$1.44 | -$3.08 |
| Income Tax Expense | $528007.00 | $963812.00 | $8.34M | -$10.29M |
| Net Income | $2.96M | -$55.28M | -$170.10M | -$497.70M |
| Net Income Ratio | $0.01 | -$0.30 | -$1.51 | -$2.94 |
| EPS | $0.01 | -$0.22 | -$0.69 | -$2.02 |
| Diluted EPS | $0.01 | -$0.22 | -$0.69 | -$2.02 |
| Weighted Avg Shares Outstanding | $247.16M | $247.16M | $247.17M | $246.22M |
| Weighted Avg Shares Outstanding (Diluted) | $247.16M | $247.16M | $247.17M | $246.22M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan